npj Breast Cancer

npj Breast Cancer is an open access peer-reviewed journal published by Nature Portfolio since 2015 under the eISSN 2374-4677, covering breast cancer research with a 2025 Journal Impact Factor of 8.4 and a first quartile rank of 44 of 333 in oncology in the Science Citation Index Expanded（npj Breast Cancer）是（Nature Portfolio）自 2015 年起出版的开放获取同行评审期刊，电子刊号 2374-4677，覆盖乳腺癌研究，2025 年影响因子为 8.4，在（SCIE）肿瘤学类 333 种期刊中列第 44 位、居第一四分位。

Scope

• The journal publishes original research, reviews and perspectives on breast cancer, including tumor biology, genetics, epidemiology, prevention, diagnosis, treatment and survivorship该刊刊载乳腺癌领域的原创研究、综述与观点，涉及肿瘤生物学、遗传学、流行病学、预防、诊断、治疗与生存者随访等方向。
• It gives particular attention to translational and clinical research that advances breast cancer care, and it welcomes interdisciplinary work linking basic cancer biology with clinical oncology, imaging and public health该刊特别关注推动乳腺癌照护的转化与临床研究，并欢迎基础癌症生物学与临床肿瘤学、成像及公共卫生交叉的研究。
• Article types include research articles, reviews, perspectives, case reports and resource articles, and the journal operates a continuous publication model with articles assigned to a single annual volume文章类型包括研究论文、综述、观点、病例报告与资源文章，该刊采用连续出版模式，文章归入单一年度卷。
• As an open access journal it applies a Creative Commons attribution licence to accepted articles and levies an article processing charge on the corresponding author, with waivers available for qualifying authors作为开放获取期刊，该刊对录用文章采用知识共享署名许可，向通讯作者收取文章处理费，并对符合条件的作者提供减免。
• Peer review is conducted single-blind and the journal follows the Nature Portfolio editorial policies on data availability, research integrity and competing interests同行评审采用单盲方式，该刊遵循（Nature Portfolio）关于数据可获取性、研究诚信与利益冲突的编辑政策。
• The journal is abstracted and indexed in the Science Citation Index Expanded, Scopus, PubMed, MEDLINE and the Directory of Open Access Journals, and it is included in the Journal Citation Reports该刊被（SCIE）、（Scopus）、（PubMed）、（MEDLINE）与开放获取期刊目录收录，并纳入期刊引证报告。

History

• The journal was launched in 2015 by Nature Portfolio in partnership with the Breast Cancer Research Foundation, as part of the npj series of open access journals that grew out of the Nature Partner Journals initiative该刊于 2015 年由（Nature Portfolio）联合乳腺癌研究基金会创办，属于源自 Nature 合作期刊计划的（npj）开放获取期刊系列。
• It was conceived to provide a dedicated open access venue for breast cancer research across the translational spectrum, and its founding editorial board drew members from cancer centres and breast cancer research programmes worldwide该刊定位为覆盖转化全谱的乳腺癌研究专门开放获取平台，首届编委来自世界各地癌症中心与乳腺癌研究项目。
• From its first year the journal operated as a gold open access title with a Creative Commons licence, and it has retained the continuous publication model since launch自创刊起该刊即为金色开放获取期刊，采用知识共享许可，并一直沿用连续出版模式。
• The Journal Impact Factor moved from 6.923 in 2021 to 7.519 in 2022, then to 7.6 in 2024 and 8.4 in 2025, maintaining first quartile standing in oncology throughout该刊影响因子由 2021 年的 6.923 升至 2022 年的 7.519，再升至 2024 年的 7.6 与 2025 年的 8.4，始终居肿瘤学类第一四分位。
• The publisher carries the journal on the Nature.com platform and the digital object identifier prefix of its articles is 10.1038, shared with other Nature Portfolio and Springer Nature journals出版方将该刊载于（Nature.com）平台，其文章的数字对象唯一标识符前缀为（10.1038），与（Nature Portfolio）及施普林格自然其他期刊一致。

Editors

• The journal is led by an editor-in-chief supported by an international editorial board whose members are drawn from breast cancer research centres, medical schools and clinical oncology programmes across the world该刊由一位主编带领，配以由世界各地乳腺癌研究中心、医学院及临床肿瘤学项目学者组成的国际编委会。
• The editorial board includes section editors responsible for subject areas such as tumor biology, breast cancer genetics, clinical oncology and epidemiology, reflecting the scope of the journal编委会设有学科编辑，分别负责肿瘤生物学、乳腺癌遗传学、临床肿瘤学与流行病学等方向，对应刊物的定位。
• Editorial handling follows the Nature Portfolio editorial management system, with submissions assigned to handling editors based on subject expertise and competing interest declarations稿件处理依托（Nature Portfolio）的编辑管理系统，依据学科专长与利益冲突声明分配责任编辑。
• Peer review is conducted single-blind and the journal maintains the Nature Portfolio standards on reviewer recruitment, conflict of interest management, data sharing and editorial independence同行评审采用单盲方式，该刊遵循（Nature Portfolio）在审稿人遴选、利益冲突管理、数据共享与编辑独立性方面的标准。
• The masthead and board roster are published on the journal page at Nature.com and updated as new members join or existing members step down编委名单在（Nature.com）期刊页公布，并随成员增减而更新。